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Summary
Background The use of non-invasive imaging to identify ruptured or high-risk coronary atherosclerotic plaques would 
represent a major clinical advance for prevention and treatment of coronary artery disease. We used combined PET 
and CT to identify ruptured and high-risk atherosclerotic plaques using the radioactive tracers ¹⁸F-sodium ﬂ uoride 
(¹⁸F-NaF) and ¹⁸F-ﬂ uorodeoxyglucose (¹⁸F-FDG).
Methods In this prospective clinical trial, patients with myocardial infarction (n=40) and stable angina (n=40) 
underwent ¹⁸F-NaF and ¹⁸F-FDG PET-CT, and invasive coronary angiography. ¹⁸F-NaF uptake was compared with 
histology in carotid endarterectomy specimens from patients with symptomatic carotid disease, and with intravascular 
ultrasound in patients with stable angina. The primary endpoint was the comparison of ¹⁸F-ﬂ uoride tissue-to-
background ratios of culprit and non-culprit coronary plaques of patients with acute myocardial infarction.
Findings In 37 (93%) patients with myocardial infarction, the highest coronary ¹⁸F-NaF uptake was seen in the culprit 
plaque (median maximum tissue-to-background ratio: culprit 1·66 [IQR 1·40–2·25] vs highest non-culprit 1·24 
[1·06–1·38], p<0·0001). By contrast, coronary ¹⁸F-FDG uptake was commonly obscured by myocardial uptake and 
where discernible, there were no diﬀ erences between culprit and non-culprit plaques (1·71 [1·40–2·13] vs 1·58 
[1·28–2·01], p=0·34). Marked ¹⁸F-NaF uptake occurred at the site of all carotid plaque ruptures and was associated 
with histological evidence of active calciﬁ cation, macrophage inﬁ ltration, apoptosis, and necrosis. 18 (45%) patients 
with stable angina had plaques with focal ¹⁸F-NaF uptake (maximum tissue-to-background ratio 1·90 [IQR 1·61–2·17]) 
that were associated with more high-risk features on intravascular ultrasound than those without uptake: positive 
remodelling (remodelling index 1·12 [1·09–1·19] vs 1·01 [0·94–1·06]; p=0·0004), microcalciﬁ cation (73% vs 21%, 
p=0·002), and necrotic core (25% [21–29] vs 18% [14–22], p=0·001).
Interpretation ¹⁸F-NaF PET-CT is the ﬁ rst non-invasive imaging method to identify and localise ruptured and high-
risk coronary plaque. Future studies are needed to establish whether this method can improve the management and 
treatment of patients with coronary artery disease.
Funding Chief Scientist Oﬃ  ce Scotland and British Heart Foundation.
Introduction
Coronary atherosclerotic plaque rupture is the principal 
precipitant of acute myocardial infarction and an important 
cause of sudden cardiac death. Rupture is challenging to 
predict because most plaques are non-obstructive and are 
not identiﬁ ed by stress testing or coronary angiography.1,2 
Atherosclerotic lesions at risk of rupture have certain 
histopathological characteristics that include positive re-
modelling, microcalciﬁ cation, and a large necrotic core.1–3 
The development of modern molecular imaging tech-
niques targeted at these features could lead to the 
identiﬁ cation of such high-risk plaques in vivo and guide 
the development of novel treatment strategies.4–7
Combined PET and CT is a non-invasive imaging 
technique that brings functional molecular imaging 
together with precise anatomical information. We have 
recently reported preliminary PET-CT data using the 
tracer ¹⁸F-sodium ﬂ uoride (¹⁸F-NaF) as a marker of 
valvular and vascular calciﬁ cation activity in patients with 
aortic stenosis.7–9 Other studies have shown the use-
fulness of ¹⁸F-ﬂ urodeoxyglucose (¹⁸F-FDG) as a surro-
gate of vascular inﬂ ammation and macrophage 
burden.6,10–13 We therefore investigated whether, compared 
with the current non-invasive gold standard of ¹⁸F-FDG, 
¹⁸F-NaF uptake could identify ruptured and high-risk 
athero sclerotic plaques in patients with symptomatic 
coronary and carotid artery disease.
Methods
Patients
Patients were recruited from the Royal Inﬁ rmary of 
Edinburgh between February, 2012, and January, 2013, in 
three cohorts: 40 patients with acute ST-segment or non-
ST-segment elevation myocardial infarction,14 40 patients 
with stable angina pectoris undergoing elective invasive 
coronary angiography, and 12 patients (nine evaluable) 
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undergoing carotid endartectomy for symptomatic caro-
tid artery disease.15
Exclusion criteria were age younger than 50 years, 
insulin-dependent diabetes mellitus, women of child-
bearing age not receiving contraception, severe renal 
failure (serum creatinine >250 μmol/L), known contrast 
allergy, and inability to provide informed consent. Only 
patients older than 50 years were recruited in the study to 
reduce any long-term risks associated with radiation 
exposure. Uncontrolled diabetes and high blood glucose 
concentrations (>11 mmol/L) interfere with the quality 
of  ¹⁸F-FDG PET imaging because of the competition 
between glucose and ¹⁸F-FDG for cellular entry. The 
convention is therefore to exclude such patients from 
vascular ¹⁸F-FDG PET studies.7,10,12,13
All patients underwent a comprehensive baseline 
clinical assessment including evaluation of their cardio-
vascular risk factor proﬁ le. Plasma troponin I concen-
trations were measured in patients with stable angina 
using the ARCHITECT STAT high-sensitivity troponin I 
assay (Abbott Laboratories, Abbott Park, IL, USA; lower 
limit of detection 1·2 ng/L; 99th percentile diagnostic 
threshold 26 ng/L). Studies were done with the approval 
of the local research ethics committee, in accordance 
with the Declaration of Helsinki, and with the written 
informed consent of each participant.
Procedures
Patients with myocardial infarction and stable angina 
underwent ¹⁸F-NaF and ¹⁸F-FDG PET-CT, CT coronary 
angiography, and CT calcium scoring (appendix).7 To 
minimise myocardial uptake, patients were instructed to 
adhere to a low-carbohydrate, high-protein, and high-fat 
diet for at least 24 h before undergoing ¹⁸F-FDG PET-CT.
Electrocardiograph-gated PET images were recon-
structed in diastole (50–75% of the R-R interval, Ultra-HD) 
using the Siemens Ultra-HD algorithm, fused with the 
CT coronary angiogram, and analysed by experienced 
observers blinded to the clinical diagnosis (NJ, MD, FC) 
using an OsiriX workstation (OsiriX version 5·5·1 64-bit; 
OsiriX Imaging Software, Geneva, Switzerland). Two-
dimensional regions of interest were drawn around all 
major (diameter >2 mm) epicardial vessels on 3 mm axial 
slices just beyond the discernible adventitial border. The 
maximum standard uptake value (the decay corrected 
tissue concentration of the tracer divided by the injected 
dose per bodyweight) was measured and corrected for 
blood pool activity in the superior vena cava to provide 
tissue-to-background ratio (TBRs) measurements. Using 
this method, we have previously shown excellent reprod-
uci bility for ¹⁸F-NaF TBR measurements in the coronary 
arteries with an intraclass correlation coeﬃ  cient of 0·99.7
We used a previously established 95% lower reference 
limit to categorise coronary plaques into ¹⁸F-NaF positive 
lesions (focal uptake with a TBR more than 25% higher 
than a proximal reference lesion) and negative plaques if 
these criteria were not achieved. This limit was based on 
our previous study, where plaques with high ¹⁸F-NaF 
uptake had maximum TBRs that were 44% (95% CI 
26–62) higher than a proximal quiescent reference 
lesion.7 In patients with acute myocardial infarction, 
¹⁸F-NaF uptake in the culprit plaque was compared with 
the highest value in any of the non-culprit vessels.
Quantiﬁ cation of ¹⁸F-FDG uptake was performed as for 
¹⁸F-NaF uptake but restricted to the proximal and mid-
portions of the coronary arteries, and to regions where 
myocardial uptake and spillover could be conﬁ dently 
excluded.7 Again, ¹⁸F-FDG positive plaques were deﬁ ned 
using the 25% threshold as described for ¹⁸F-NaF. Eﬀ ective 
myocardial suppression of ¹⁸F-FDG was predeﬁ ned as a 
standard uptake value of 5·0 or less in the basal ventricular 
septum (appendix) as per published data.12
In patients with stable angina, PET-CT imaging was 
prospectively used to direct greyscale and radio-
frequency intravascular ultrasound (20 MHz Eagle Eye 
Platinum Catheters [Volcano Corp, San Diago, CA, 
USA], motorised pull-back 0·5 mm/s) to the ¹⁸F-NaF 
positive and negative plaques. The interventional 
cardiologist acquiring the intravascular ultrasound data 
was blinded to the PET-CT status of the plaque.
Intravascular ultrasound analysis was done as described 
previously16 using dedicated VIAS software (Volcano 
Image Analysis Software version 3.0) by operators blinded 
to the PET data. Regions of interest were drawn around 
the external elastic membrane and luminal borders, and 
plaque area and composition (dense calcium, necrotic 
core, ﬁ bro-fatty tissue, and ﬁ brous tissue) calculated.16–18 
The presence of microcalciﬁ cation (spotty calciﬁ cation in 
the absence of acoustic shadowing on three or more 
consecutive frames) and the maximum frame necrotic 
core (the highest percentage of necrotic core on a single 
frame) were recorded.19 The remodelling index was 
deﬁ ned as the ratio between the external elastic mem-
brane cross-sectional area of the lesion and a proximal 
reference region in the same vessel.20 Plaques were 
classiﬁ ed as thin-cap ﬁ broatheroma, thick-cap ﬁ bro-
atheroma, pathological intimal thickening, or ﬁ brocalciﬁ c 
plaque as deﬁ ned previously.18,21
CT analysis was done on a dedicated cardiovascular 
workstation (Vital Images, Minnetonka, MN, USA). 
Vessel-speciﬁ c and total Agatston calcium scores were 
calculated as described previously.7 An independent 
experienced and blinded observer (MW) determined the 
stenosis severity, plaque composition (calciﬁ ed, non-
calciﬁ ed, mixed plaque), and presence of high-risk CT 
features (positive remodelling, microcalciﬁ cation, necro-
tic core) according to standard deﬁ nitions in plaques 
with and without increased ¹⁸F-NaF activity.22
Intact atherosclerotic plaques were retrieved at the 
time of carotid endarterectomy and scanned using ex-
vivo PET-CT to allow precise anatomical co localisation of 
¹⁸F-NaF activity with pathological evidence of plaque 
rupture. Plaques were divided into ¹⁸F-NaF positive and 
negative areas, and histological sections were assessed 
See Online for appendix
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using Movat’s pentachrome and immunohistochemistry 
to investigate calciﬁ cation activity (tissue non-speciﬁ c 
alkaline phosphatase and osteocalcin), macrophage 
inﬁ ltration (CD68), and cell death (apoptosis, cleaved 
caspase 3; presence of necrotic core; appendix).
Statistical analysis
The primary endpoint of the study was the comparison of 
¹⁸F-ﬂ uoride tissue-to-background ratios of culprit and non-
culprit coronary plaques of patients with acute myocardial 
infarction. The main secondary endpoints were com-
parative imaging and histol ogical characterisation of 
¹⁸F-ﬂ uoride positive and negative atherosclerotic plaques 
in patients with coronary and carotid artery disease. Based 
on our previous data,7 we required 36 patients with myo-
cardial infarction to detect a diﬀ erence of 0·23 in the 
tissue-to-background ratio between culprit and non-culprit 
plaques at 90% power and two-sided p<0·05. We recruited 
40 patients to account for incomplete data and recruited a 
similar sized (n=40) comparator group of patients with 
stable angina.
Continuous data were tested for normality with the 
D’Agostino-Pearson omnibus test. Continuous para-
metric variables were expressed as mean (SD) and 
Myocardial infarction Stable angina
All (n=40)
All (n=40) STEMI (n=26) NSTEMI (n=14)
Age in years, mean (SD) 62 (8) 63 (9) 60 (8) 67 (8)
Men, n (%) 37 (93%) 24 (92%) 13 (93%) 36 (90%)
Body-mass index (kg/m²), mean (SD) 28 (5) 27 (5) 30 (4) 30 (5)
Antecedent angina (active), n (%) 9 (23%) 5 (19%) 4 (29%) 40 (100%)
Heart rate (per min), mean (SD)* 56 (7) 56 (7) 56 (7) 59 (9)
Systolic blood pressure (mm Hg), mean (SD) 132 (21) 131 (20) 121 (21) 134 (14)
Diastolic blood pressure (mm Hg), mean (SD) 76 (9) 76 (9) 76 (8) 77 (10)
Cardiovascular history, n (%)
Previous MI 5 (13%) 1 (4%) 4 (29%) 15 (38%)
Previous CVA/TIA 2 (5%) 1 (4%) 1 (7%) 4 (10%)
Previous PCI 5 (13%) 2 (8%) 3 (21%) 19 (48%)
Previous CABG 2 (5%) 2 (8%) 0 11 (28%)
Risk factors, n (%)
Smoking habit (ex or current) 25 (63%) 19 (73%) 6 (43%) 24 (60%)
Non-insulin dependent diabetes 8 (20%) 7 (27%) 1 (7%) 13 (33%)
Hypertension 17 (43%) 11 (42%) 6 (43%) 36 (90%)
Hypercholesterolaemia 19 (48%) 11 (42%) 8 (57%) 39 (98%)
Medications, n (%)†
Aspirin 40 (100%) 26 (100%) 14 (100%) 33 (83%)
Clopidogrel 39 (98%) 25 (96%) 14 (100%) 5 (13%)
Statin 39 (98%) 26 (100%) 13 (93%) 36 (90%)
β blocker 32 (80%) 20 (77%) 12 (86%) 28 (70%)
ACEI/ARB 35 (88%) 25 (96%) 10 (71%) 20 (50%)
Calcium channel blockers 2 (5%) 2 (8%) 0 16 (40%)
Other anti-hypertensive 3 (8%) 1 (4%) 2 (14%) 6 (15%)
Oral nitrates 1 (3%) 0 1 (7%) 15 (38%)
Serum biochemistry, mean (SD)
Cholesterol (mmol/L) 4·7 (1·2) 4·7 (1·3) 4·8 (1·1) 3·9 (0·8)
HDL cholesterol (mmol/L) 1·1 (0·3) 1·1 (0·3) 1·0 (0·3) 1·1 (0·3)
LDL cholesterol (mmol/L) 2·9 (1·1) 2·8 (1·1) 3·1 (1·0) 2·1 (0·7)
Triglycerides (mmol/L) 1·6 (0·8) 1·7 (0·7) 1·5 (0·7) 1·6 (0·7)
Creatinine (μmol/L) 84 (27) 86 (29) 82 (24) 85 (23)
Coronary artery calcium score (Agatston units), 
median (IQR)
159 (42–456) 176 (45–474) 122 (26–442) 599 (60–1302)
Peak troponin concentration (ng/L), median (IQR) 32 300 (10 200–50 000) 11 200 (3300–50 000) 3800 (1000–9200)
NSTEMI=non-ST elevation myocardial infarction. MI=myocardial infarction. CVA=cerebrovascular accident. TIA=transient ischaemic attack. PCI=percutaneous coronary 
intervention. ACEI=angiotensin converting enzyme inhibitor. ARB=angiotensin receptor blocker. CABG=coronary artery bypass graft. HDL=high-density lipoprotein. 
LDL=low-density lipoprotein. STEMI=ST-elevation myocardial infarction. *Heart rate at the time of CT coronary angiography. †Medications at the time of scan. 
Table 1: Baseline characteristics of patients with coronary artery disease
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compared using Student’s t tests. Non-parametric data 
were presented as median (IQR) and compared using 
Mann-Whitney U test or Wilcoxon signed-rank test as 
appropriate. Fisher’s exact test or chi-squared test was 
used for analysis of categorical variables. Statistical 
analysis was done with Graph Pad Prism version 5 
(GraphPad Software, La Jolla, CA, USA). A two-sided 
p<0·05 was taken as statistically signiﬁ cant.
The study was registered with ClinicalTrials.gov 
number NCT01749254.
Role of the funding source
The funding source had no role in the study design 
(except through its external peer review process), data 
collection, data analysis, data interpretation, or writing of 
the report. All authors had access to the primary data and 
have ﬁ nal responsibility to submit for publication.
Results
Patients were predominantly middle-aged men and had 
multiple cardiovascular risk factors (table 1). They under-
went both ¹⁸F-NaF (60 [SD 9] min after 123 [SD 5] MBq) 
and ¹⁸F-FDG (90 [7] min after 192 [11] MBq) PET-CT 
scanning within a median of 6 (IQR 3–9) days. The 
median duration between PET-CT scanning and coronary 
angiography was 7 (IQR 1–12) days. The total eﬀ ective 
radiation dose from study participation was 13·7 (SD 3·0) 
mSv (conversion factor of 0·014 mSv/mGy.cm): ¹⁸F-NaF 
(3·8 [SD 0·3] mSv) and ¹⁸F-FDG (4·9 [0·5] mSv) PET-CT, 
CT coronary angiogram (3·7 [2·1] mSv), and calcium 
score (1·3 [0·5] mSv).
The culprit vessel was the left anterior descending 
artery in 17 (42%) patients, the left circumﬂ ex artery in 
seven (18%), and the right coronary artery in 16 (40%). 
Patients underwent ¹⁸F-NaF scans 6 [IQR 3–10] days after 
hospitalisation for myocardial infarction (symp toms to 
¹⁸F-NaF scan, 8 [3–10] days). ¹⁸F-NaF activity in the culprit 
plaque was 34% higher than the maxi mum activity 
recorded anywhere else in the coronary vasculature 
(maximum TBR 1·66 [1·40–2·25] vs 1·24 [1·06–1·38], 
p<0·0001; ﬁ gures 1 and 2). In 37 of the 40 patients (93%), 
increased ¹⁸F-NaF uptake was seen in the culprit plaque 
(ﬁ gure 1; appendix). In the three patients without uptake, 
two were younger smokers (aged 50 and 52 years) and, in 
the third, the culprit lesion was adjudicated as the right 
coronary artery although focal increased activity was seen 
in the left circumﬂ ex artery. In ﬁ ve patients, increased 
¹⁸F-NaF activity was seen at multiple sites within the 
coronary circulation.
Predeﬁ ned myocardial suppression of ¹⁸F-FDG uptake 
was achieved in 28 (70%) patients (median myocardial 
standard uptake value 3·92 [IQR 2·71–5·55]). However, 
coronary ¹⁸F-FDG uptake could not be distinguished 
from patchy myocardial uptake in 22 patients aﬀ ecting 
52% of vessel territories. Increased uptake of ¹⁸F-FDG 
was observed in the culprit vessels of six (33%) of the 
remaining 18 patients. Overall, no signiﬁ cant diﬀ erences 
could be shown between the maximum TBRs in the 
culprit plaques and those recorded elsewhere in the 
coronary vasculature (1·71 [IQR 1·40–2·13] vs 1·58 
[1·28–2·01], p=0·34: ﬁ gure 2) with a mean diﬀ erence of 
0·09 (95% CI −0·07 to 0·24).
The median duration between clinical symptoms and 
carotid endarterectomy was 17 [IQR 10–27] days (appen-
dix). Carotid endarterectomy specimens (ﬁ gure 3; appen-
dix) were obtained for 12 patients, although three 
specimens could not be excised intact and were discarded. 
Ex-vivo ¹⁸F-NaF PET-CT was undertaken in nine speci-
mens and uptake was localised to the site of macroscopic 
plaque rupture in all patients (ﬁ gure 3). Compared with 
sections of tissue without uptake (n=15), those with 
increased ¹⁸F-NaF uptake (n=24) had increased calciﬁ -
cation activity (tissue non-speciﬁ c alkaline phosphatase 
4·07% [SD 3·42] vs 0·76% [0·51], p<0·0001; osteocalcin 
1·88% [IQR 0·58–4·10] vs 0·25% [0·11–0·58], p<0·0001), 
macrophage inﬁ ltration (CD68, 350 [IQR 172–840] vs 
145 [24–362] cells/mm², p=0·013), and cell death (apop-
tosis, cleaved-caspase-3, 1·23% [0·69–1·91] vs 0·09% 
[0·04–1·38], p=0·005; necrotic core, 22/24 vs 4/15; 
p<0·0001; appendix).
Patients with stable angina were older (67 [SD 8] vs 62 [8] 
years, p=0·006) and had more severe coronary artery 
disease (coronary artery calcium score 599 [IQR 60–1302] 
vs 159 [42–456] Agatston units, p=0·006) than those with 
myocardial infarction (table 1). Focal ¹⁸F-NaF uptake was 
noted in 18 patients (45%), which did not seem to be 
related to percutaneous coronary intervention and stent 
Figure 1: Focal ¹⁸F-ﬂ uoride and ¹⁸F-ﬂ uorodeoxyglucose uptake in patients 
with myocardial infarction and stable angina
Patient with acute ST-segment elevation myocardial infarction with (A) proximal 
occlusion (red arrow) of the left anterior descending artery on invasive coronary 
angiography and (B) intense focal ¹⁸F-ﬂ uoride (¹⁸F-NaF, tissue-to-background 
ratios, culprit 2·27 versus reference segment 1·09 [108% increase]) uptake 
(yellow-red) at the site of the culprit plaque (red arrow) on the combined positron 
emission and computed tomogram (PET-CT). Corresponding 
¹⁸F-ﬂ uorodeoxyglucose PET-CT image (C) showing no uptake at the site of the 
culprit plaque (¹⁸F-FDG, tissue-to-background ratios, 1·63 versus reference 
segment 1·91 [15% decrease]). Note the signiﬁ cant myocardial uptake overlapping 
with the coronary artery (yellow arrow) and uptake within the oesophagus 
(blue arrow). Patient with anterior non-ST-segment elevation myocardial 
infarction with (D) culprit (red arrow; left anterior descending artery) and 
bystander non-culprit (white arrow; circumﬂ ex artery) lesions on invasive coronary 
angiography that were both stented during the index admission. Only the culprit 
lesion had increased ¹⁸F-NaF uptake (¹⁸F-NaF, tissue-to-background ratios, culprit 
2·03 versus reference segment 1·08 [88% increase]) on PET-CT (E) after 
percutaneous coronary intervention. Corresponding ¹⁸F-ﬂ uorodeoxyglucose 
PET-CT showing no uptake either at the culprit (¹⁸F-FDG, tissue-to-background 
ratios, culprit 1·62 versus reference segment 1·49 [9% increase]) or the bystander 
stented lesion. Note intense uptake within the ascending aorta. In a patient with 
stable angina with previous coronary artery bypass grafting, invasive coronary 
angiography (G) showed non-obstructive disease in the right coronary artery. 
Corresponding PET-CT scan (H) showed a region of increased ¹⁸F-NaF activity 
(positive lesion, red line) in the mid-right coronary artery (tissue-to-background 
ratio, 3·13) and a region without increased uptake in the proximal vessel (negative 
lesion, yellow line). Radiofrequency intravascular ultrasound shows that the 
¹⁸F-NaF negative plaque (I) is principally composed of ﬁ brous and ﬁ brofatty tissue 
(green) with conﬂ uent calcium (white with acoustic shadow) but little evidence of 
necrosis. On the contrary, the ¹⁸F-NaF positive plaque (J) shows high-risk features 
such as a large necrotic core (red) and microcalciﬁ cation (white).
Articles
www.thelancet.com  Vol 383   February 22, 2014 709
deployment (appendix). The maximum TBR for ¹⁸F-NaF 
positive plaques was 1·90 [IQR 1·61–2·17] and for ¹⁸F-NaF 
negative plaques was 1·02 [0·82–1·17]. ¹⁸F-NaF positive 
plaques were predominantly (72% of patients) non-
obstructive (<70% luminal stenosis) on coronary 
angiography and showed multiple high-risk features on 
radiofrequency intravascular ultrasound (positive 
remodelling [remodelling index 1·12 [IQR 1·09–1·19] vs 
A B C
D E F
G H I
J
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1·01 [0·94–1·06]; p<0·001, microcalciﬁ cation (73 vs 21%, 
p=0·002) and necrotic core (24·6% [20·5–28·8] vs 18·0% 
[14·0–22·4]), p=0·001), with similar observations for CT 
(ﬁ gure 1, table 2; appendix). Multivessel uptake was 
commonly seen: two-vessel uptake in six (15%) and three-
vessel uptake in ﬁ ve (13%) patients. Patients with ¹⁸F-NaF 
positive lesions had higher concentrations of plasma 
troponin at baseline (3·35 [IQR 2·35–10·20] vs 2·45 
[1·85–4·02] ng/L; p=0·047), with one individual having a 
concentration (35 ng/L) above the 99th percentile 
diagnostic threshold.
Although predeﬁ ned myocardial suppression of 
¹⁸F-FDG uptake was achieved in 34 (85%) patients 
(median myocardial standard uptake value 2·60 
[IQR 1·83–3·83]), coronary ¹⁸F-FDG uptake could not be 
conﬁ dently interpreted in 45% of vessel territories. 
Increased focal ¹⁸F-FDG uptake was noted in just four 
patients: three at the site of recent coronary stenting and 
one at the ostium of a saphenous vein graft.
Discussion
We have shown that intense ¹⁸F-NaF uptake localises to 
recent plaque rupture in patients with acute myocardial 
infarction and in those with symptomatic carotid disease. 
Moreover, in patients with stable coronary artery disease, 
¹⁸F-NaF uptake seems to identify coronary plaques with 
high-risk features on intravascular ultrasound. This 
technique holds major promise as a means of identifying 
high-risk and ruptured plaque, and potentially informing 
the future management and treatment of patients with 
stable and unstable coronary artery disease.
Figure 3: Carotid ¹⁸F-ﬂ uoride uptake and carotid plaque rupture
In-vivo (A and B) and ex-vivo (C and D) positron emission and computed tomograms showing colocalisation of ¹⁸F-ﬂ uoride (¹⁸F-NaF) uptake (yellow-orange) to the 
site of plaque rupture with adherent thrombus on excised carotid endarterectomy tissue (E and F). Histology of the ¹⁸F-NaF-positive region shows a large necrotic 
core (Movat’s pentachrome, magniﬁ cation 4×, G), within which increased staining for tissue non-speciﬁ c alkaline phosphatase can be seen as a marker of calciﬁ cation 
activity on immunohistochemistry (magniﬁ cation 4×, H; magniﬁ cation 10×, I).
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Figure 2: ¹⁸F-ﬂ uoride and ¹⁸F-ﬂ uorodeoxyglucose uptake in patients with myocardial infarction
¹⁸F-ﬂ uoride activity (maximum tissue-to-background ratio) was increased in the culprit plaque (red) compared 
with the maximum uptake in any of the non-culprit plaques (blue). By contrast, there was no diﬀ erence in the 
activity of ¹⁸F-ﬂ uorodeoxyglucose between these regions.
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Over 90% of our patients with myocardial infarction 
had increased ¹⁸F-NaF uptake at the site of their culprit 
ruptured plaque, with TBR values that were a third 
higher than the maximum activity anywhere else in the 
coronary vasculature. These ﬁ ndings were not unique to 
the coronary circulation since we also noted increased 
focal ¹⁸F-NaF uptake at the site of plaque rupture in all 
excised carotid endarterectomy specimens from patients 
with symptomatic carotid disease. However, we do 
acknowledge that this was not a universal ﬁ nding. Of the 
three patients with myocardial infarction who had no 
uptake, two were younger smokers with only mild under-
lying irregularities on coronary angiography, implicating 
plaque erosion and thrombosis as the mechanism of 
their infarction rather than plaque rupture.23 The third 
patient sustained an inferolateral non-ST segment 
elevation myocardial infarction and had a lesion stented 
in the right coronary artery. Increased ¹⁸F-NaF activity 
was seen in the co-dominant circumﬂ ex artery that could 
have equally explained the clinical presentation, raising 
the intriguing possibility that ¹⁸F-NaF might have a 
clinical role for patients in whom the culprit lesion is not 
readily apparent.
Focal regions of increased ¹⁸F-NaF activity were seen in 
almost a half of our patients with stable coronary artery 
disease. To understand the mechanism of uptake in these 
patients, we sought to compare plaque characteristics of 
lesions with and without increased ¹⁸F-NaF uptake. 
Because histology of the coronary arteries in this 
population is not feasible, we undertook greyscale and 
radiofrequency intravascular ultrasound, a widely used 
and validated process that provides detailed characterisation 
of plaque composition.21 This method showed that lesions 
with increased ¹⁸F-NaF uptake were associated with greater 
positive remodelling, more microcalciﬁ cation, and a larger 
necrotic core. These ﬁ ndings were corroborated by, and 
consistent with, the ﬁ ndings of plaque analysis done with 
CT coronary angiography. Plasma troponin concentrations 
measured by a novel high-sensitivity assay were also 
higher in those patients with ¹⁸F-NaF positive plaques than 
in patients with ¹⁸F-NaF negative plaques, perhaps impli-
cating subclinical plaque rupture with embolisation and 
microinfarction.
Why does ¹⁸F-NaF bind to ruptured or high-risk 
plaque? Similar to the caseating granulomata of tuber-
culosis, atherosclerotic vascular calciﬁ cation is a con-
trolled cellular response to an intense, necrotic, and 
chronic inﬂ ammatory stimulus. Indeed, direct links 
between inﬂ ammatory cells and osteoblastic metaplasia 
in the vasculature are well described.24,25 Hydroxyapatite 
is the central structural component of vascular calciﬁ -
cation and is laid down during the earliest and most 
active stages of mineralisation:24 hydroxyapatite nano-
crystals nucleate, propagate, and mineralise the extra-
cellular matrix. Fluoride ions are incorporated into the 
hydroxyapatite by ion exchange with hydroxyl groups at 
the crystal surface. This process is dependent on the 
crystal surface area that will be greatest in the earliest 
and most active nanocrystalline stages of mineralisation 
associated with plaque inﬂ ammation and necrosis. We 
believe that these processes are responsible for the 
observed ¹⁸F-NaF uptake and is consistent with our 
data showing ¹⁸F-NaF uptake in regions of necrosis, 
macrophage inﬁ ltration, apoptosis, microcalciﬁ cation, 
and alkaline phosphatase and osteocalcin staining. 
Moreover, mathematical modelling indicates that micro-
calciﬁ cation at the surface of thin-capped atheroma 
(ﬁ gure 1) can intensify and double incident stresses.26 
Microcalciﬁ cation is therefore not only a marker of acute 
plaque rupture but is implicated in its precipitation.
Coronary arterial calciﬁ cation is considered patho-
gnomonic of atherosclerosis and is a powerful indepen-
dent risk predictor for cardiovascular events that can be 
further reﬁ ned by the rapidity of its progression.27,28 Why 
then not rely on CT coronary calcium scoring alone as a 
biomarker? Microcalciﬁ cation cannot be detected on 
CT and conﬂ uent coronary macrocalciﬁ cation develops 
slowly, taking many months or years to become apparent 
on CT, and can become dormant once inﬂ ammation in 
¹⁸F-ﬂ uoride positive 
plaques (n=15)
¹⁸F-ﬂ uoride negative 
plaques (n=24)
p
Lumen
Area (mm²) 9·0 (5·7–13·5) 6·7 (4·7–9·7) 0·078
Minimal diameter (mm) 2·6 (1·7–3·1) 1·9 (1·7–2·6) 0·165
Maximum diameter (mm) 4·9 (4·1–5·3) 3·6 (3·1–4·6) 0·006
Vessel
Area (mm²) 24·1 (17·2–27·1) 14·5 (11·9–18·1) 0·002
Minimal diameter (mm) 4·4 (3·4–5·2) 3·6 (3·0–4·1) 0·057
Maximum diameter (mm) 6·5 (6·0–7·1) 5·2 (4·7–5·9) 0·0001
Plaque
Length (mm) 14·2 (6·2–23·5) 15·2 (6·7–25·0) 0·941
Volume (mm³) 152·9 (99·6–289·7) 91·0 (45·8–158·2) 0·032
Burden (%)* 55·6 (48·6–64·4) 54·2 (46·3–57·3) 0·174
Remodelling index 1·12 (1·09–1·19) 1·01 (0·94–1·06) 0·0004
Plaque composition
Fibrous tissue (%) 51·0 (46·3–56·6) 58·1 (51·6–65·5) 0·015
Fibro-fatty (%) 10·9 (6·0–13·8) 12·6 (9·3–17·8) 0·092
Necrotic core (%) 24·6 (20·5–28·8) 18·0 (14·0–22·4) 0·001
Maximum frame necrotic core (%)† 35·5 (34·2–40·5) 29·2 (23·9–42·1) 0·009
Dense calcium (%) 12·6 (9·1–18·1) 10·2 (4·0–14·9) 0·092
Microcalciﬁ cation, n (%) 11 (73%) 5 (21%) 0·002
Plaque classiﬁ cation, n (%)
Thin-cap ﬁ broatheroma 7 (47%) 4 (16%) 0·068
Thick-cap ﬁ broatheroma 5 (33%) 9 (38%) 1·0
Pathological intimal thickening 0 7 (29%) 0·003
Fibrocalciﬁ c plaque 3 (20%) 4 (16%) 1·0
Data are median (IQR) unless otherwise stated. *Plaque burden calculation = (average vessel area − average lumen area) 
/average vessel area. †Maximum necrotic core in any single frame in the plaque.
Table 2: Greyscale and radiofrequency intravascular ultrasound characteristics in ¹⁸F-ﬂ uoride positive and 
negative plaques of patients with stable angina
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the plaque has subsided. By identifying areas of nascent 
and ongoing calciﬁ cation activity, ¹⁸F-NaF uptake allows 
us to detect regions of metabolically active plaque, thus 
providing complementary information to CT.29–32 Indeed, 
we noted large areas of coronary CT calcium in the 
absence of increased ¹⁸F-NaF uptake (ﬁ gure 1) whereas 
other regions with minimal or no CT calcium had intense 
¹⁸F-NaF uptake (appendix) in keeping with previous 
observations in the aorta by Derlin and colleagues 
(panel).29,32 Moreover, given that ¹⁸F-NaF seems more 
closely aligned with the process of necrotic inﬂ ammation 
and plaque metabolic activity, we believe that it potentially 
oﬀ ers major improvements to the prediction of cardio-
vascular risk compared with calcium scoring.
Our data have already established that ¹⁸F-NaF identiﬁ es 
plaque with multiple high-risk features, but prospective 
studies are now needed in a broad range of patients to 
assess whether increased coronary ¹⁸F-NaF activity will 
ultimately translate into future adverse events. If the 
results prove conﬁ rmatory then this technique has the 
potential to fundamentally alter the way we treat coronary 
artery disease: moving us away from the current framework 
based on lesion severity and ischaemia to one focused on 
plaque metabolism and inﬂ ammation. It could, for 
example, permit the identiﬁ cation of the vulnerable patient 
with single or multiple high-risk or silently ruptured 
plaques, providing an opportunity to treat and modify their 
risk to prevent future adverse cardiovascular events.
By contrast with ¹⁸F-NaF, ¹⁸F-FDG imaging was ham-
pered by problems related to tracer uptake in the 
myocardium. Our stringent dietary recommendations 
resulted in suppression of myocardial activity in 70–85% 
of patients: a rate that compares favourably with pre-
vious studies (57–84%).6,12,13 However, this suppression 
resulted in a patchy distribution of myocardial uptake 
that frequently obscured activity in one or more coronary 
vessels. Increased ¹⁸F-FDG uptake might possibly occur 
in the culprit plaque and we failed to show this because 
of incomplete data or the delay in scanning. However, 
given its limitations, we believe that ¹⁸F-FDG is unlikely 
to become suﬃ  ciently robust to permit its clinical appli-
cation to the coronary circulation. Nevertheless, ¹⁸F-FDG 
uptake remains an important measure of general 
vascular inﬂ ammation in the aorta and carotid arteries, 
providing complementary and distinct metabolic infor-
mation to that of ¹⁸F-NaF uptake.
We acknowledge that there are limitations of our study 
that include a lack of respiratory gating, potential partial 
volume artefacts, and the use of surrogate measures for 
coronary histology.21 However, we believe that the totality 
of our comprehensive evidence using multiple approaches 
and imaging modalities provides a robust and cogent 
argument to support our contention that ¹⁸F-ﬂ uoride 
uptake identiﬁ es vulnerable and high-risk plaques in 
patients with stable and unstable coronary heart disease. 
Further work is now needed to establish whether ¹⁸F-NaF 
PET-CT will provide a clinically useful technique capable 
of improving risk stratiﬁ cation, monitoring disease pro-
gression, guiding therapeutic interventions, and assessing 
novel anti-atherosclerotic therapies.
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Panel: Research in context
Systematic review
We searched PubMed using variations of the keywords “high-risk plaques”, “vulnerable 
plaques”, “ruptured plaques”, “¹⁸F-ﬂ uorodeoxyglucose positron emission tomography”, 
“¹⁸F-ﬂ uoride positron emission tomography”, and “coronary arteries”. The search was 
restricted to human studies. We assessed the quality of the evidence speciﬁ cally related to 
cardiovascular disease by reviewing the patient population studied and the methodology 
for the positron emission and CT imaging.
Non-invasive imaging of carotid plaque inﬂ ammation using ¹⁸F-ﬂ uorodeoxyglucose 
positron emission tomography was reported by Rudd and colleagues in 2002.11 Since then, 
this tracer has been validated and widely used as a surrogate of large vessel inﬂ ammation.8,10 
Increased ¹⁸F-ﬂ uorodeoxyglucose in the coronary arteries has been described in patients with 
coexisting malignancy.12,33,34 Since then, three prospective studies have examined the 
feasibility and reproducibility of assessing uptake of this tracer in the coronary 
vasculature.6,7,13 Only two small studies (n=10–20)6,13 have suggested that 
¹⁸F-ﬂ uorodeoxyglucose might identify some inﬂ amed plaques in patients with recent 
myocardial infarction, although the largest study showed that in 50% of patients with acute 
myocardial infarction, there was no uptake of ¹⁸F-ﬂ uorodeoxyglucose in the culprit plaque.13
Four retrospective studies in patients with cancer have recently reported cardiovascular 
uptake of ¹⁸F-ﬂ uoride.29,31,32,35 The aortic uptake of ¹⁸F-NaF was ﬁ rst reported by Derlin and 
colleagues29 and cardiac ¹⁸F-ﬂ uoride uptake by Beheshti and colleagues.31 We reported the 
coronary uptake of ¹⁸F-NaF in a prospective clinical trial involving patients with aortic 
stenosis,7,8 and these results were subsequently corroborated by Li and colleagues in their 
retrospective study of patients with cancer.30 No study has prospectively assessed this tracer 
in patients with stable or unstable coronary artery disease or validated its activity against 
histology or invasive intracoronary imaging, such as intravascular ultrasound. There are no 
previous reports of ¹⁸F-ﬂ uoride uptake in relation to plaque vulnerability or rupture.
Interpretation
There are currently no non-invasive imaging techniques that can identify high-risk and 
ruptured coronary atherosclerotic plaques in vivo in patients with coronary heart disease. For 
the ﬁ rst time, we have shown that ¹⁸F-ﬂ uoride positron emission tomography can identify 
culprit and ruptured plaques in patients with myocardial infarction and symptomatic carotid 
disease. Moreover, histological characterisation demonstrates that ¹⁸F-ﬂ uoride activity 
localises to regions of plaque rupture with evidence of increased inﬂ ammation, calciﬁ cation 
activity, necrosis, and cell death. In patients with stable angina, ¹⁸F-ﬂ uoride is associated with 
coronary plaques that have high-risk features on intravascular ultrasound, including positive 
remodelling, microcalciﬁ cation, and necrosis. Given its ability to identify high-risk or 
ruptured coronary atherosclerotic plaque, this non-invasive imaging technique has the 
potential to change how we identify, manage, and treat patients with stable and unstable 
coronary artery disease. Further work is now needed to establish whether ¹⁸F-ﬂ uoride 
positron emission tomography will provide a means of improving risk stratiﬁ cation, 
monitoring disease progression, guiding therapeutic interventions, and assessing novel 
anti-atherosclerotic therapies.
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